Jazz Singing A Stronger Oncology Tune Through Celator Buy
Jazz has added to its oncology portfolio through a $1.5bn purchase of Celator Pharmaceuticals – developer of acute myeloid leukemia drug, Vyxeos (cytarabine/daunorubicin liposome injection).
Jazz has added to its oncology portfolio through a $1.5bn purchase of Celator Pharmaceuticals – developer of acute myeloid leukemia drug, Vyxeos (cytarabine/daunorubicin liposome injection).